“Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data from more recent years are ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Please provide your email address to receive an email when new articles are posted on . Less than 40% of the studied veteran cohort were adherent to their inhaled COPD medications. Adherence was found ...

Medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) is associated with increasing COPD symptoms, hospitalizations, morbidity, mortality, and health care ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. Americans facing a tough job market in 2025 won’t get a break ...